Immune Monitor - October 2022

A Message from the President

Dear Colleagues,

It’s hard to believe we are just a few weeks away from the 37^th Annual Meeting & Pre-Conference Programs, taking place Nov. 8-12 in Boston, MA and virtually. We saw a record number of abstracts accepted, almost 1,500, and I can’t wait to see what else is in store for the immuno-oncology community at the meeting.

Taking a look at the abstracts, cellular therapies is a standout theme for this year’s meeting. Over the course of the past year, the society has elevated our cellular therapy content and I’m thrilled to see the participation in this topic from so many members and abstract authors. Moreover, the Annual Meeting will highlight cutting-edge science from tumor immunology and cancer immunotherapy as a whole.

In addition to the hottest science, the meeting provides our community with a wonderful opportunity to come together for networking. I thoroughly enjoy the opportunity to catch up with friends and colleagues in between sessions, during dedicated networking and, of course, at The CheckPoints Party! The band is ready to take the stage at the Omni Boston Hotel on Friday, Nov. 11 at 8:30 p.m. Take a look at our highlight video and be sure to get your merch ahead of the show as all proceeds go to support the Forward Fund.

Value Framework for Phase III Immuno-Oncology Trials

SITC published a new manuscript to assist investigators in selecting phase III trials with high potential value to their patients and to the immuno-oncology field for activation within their institutions based on the robustness of the mechanism and biology, early clinical evidence, and trial design for a given study.

The manuscript, “Maximizing the value of phase III trials in immuno-oncology: A checklist from the Society for Immunotherapy of Cancer (SITC),” is now available in the Journal for ImmunoTherapy of Cancer.

Learn More

ADVERTISEMENT

So, what are you most looking forward to at SITC 2022? I’d love to hear from you on social media — be sure to use #SITC22! Here’s to convening the immuno-oncology field for what is sure to be a memorable and robust meeting. See you in a few weeks.

Sincerely,

Patrick Hwu, MD
SITC President

Join Us in Boston at SITC 2022

Join us at the Society for Immunotherapy of Cancer’s (SITC) 37th Annual Meeting & Pre-Conference Programs (SITC 2022) taking place Nov. 8–12, 2022, at the Boston Convention and Exhibition Center in Boston, MA. Virtual participation is also available at the same registration rates.

With a record number of abstracts this year, almost 1,500, the science is sure to be amazing for all who attend!

Poster Reception & Meet the Fellows of the Academy of Immuno-Oncology

Join the Fellows of the Academy of Immuno-Oncology (FAIO) for a casual social networking event in the Exhibit and Poster Hall. All attendees are invited to meet this year’s inductees. The Academy of Immuno-Oncology was established by SITC to honor individuals who have launched the field of cancer immunotherapy into the breakthrough cancer treatment it is today and bring together the brightest minds in the field to continue to advance SITC, the field, and the next generation of immuno-oncologists. See the list of Fellows here.

Awards Ceremonies

The Society for Immunotherapy of Cancer's (SITC) 37^th Annual Meeting Awards Ceremonies celebrate the achievements of current and future leaders in the cancer immunotherapy field. The work of

these dedicated individuals seeks to propel the field forward and build a solid foundation for future advances and soon, a cure. Celebrate your colleagues at three Awards Ceremonies:

Thursday, Nov. 10 from 7:40–8 a.m. EST Friday, Nov. 11 from 8–8:20 a.m. ESTFriday, Nov. 11 from 6:30–7 p.m. EST

Session 202: Keynote Address – From the Clinic to the Lab: Investigating Mechanisms of Response and Resistance to Immune Checkpoint Therapy

Padmanee Sharma, MD, PhD – The University of Texas MD Anderson Cancer CenterFriday, Nov. 11 at 8:20–9:10 a.m. ET

The Keynote Address, presented by Padmanee Sharma, MD, PhD (The University of Texas MD Anderson Cancer Center) will be a highlight of SITC 2022. Dr. Sharma’s research focus is on

investigating mechanisms and pathways within the immune system that are responsible for tumor rejection and clinical benefit. Her lab continues to design innovative trials to evaluate human immune responses to different immunotherapies and she is the Principal Investigator for multiple immunotherapy clinical trials that focus on translational laboratory studies. Her studies have identified novel resistance mechanisms, which enable development of rational combination immunotherapy strategies for the treatment of cancer patients.

Additional SITC 2022 Highlights You Don't Want to Miss: